A recent report by the World Health Organization (WHO) sheds light on Nigeria’s mounting hepatitis crisis, with an estimated 20 million citizens living with chronic hepatitis B or C.
While the global number of new infections is declining, the low diagnosis and treatment rates in Nigeria are cause for alarm. Only a tiny fraction of those infected receive the care they need.
Nigeria among the global epicenters
The WHO report identifies Nigeria among the ten countries bearing the heaviest load of viral hepatitis B and C worldwide, alongside China, India, Indonesia, Pakistan, Ethiopia, Bangladesh, Vietnam, the Philippines, and the Russian Federation.
The report reveals that just 13 per cent of Nigerians with chronic hepatitis B have been diagnosed, and a mere 3 per cent have access to antiviral therapy. The situation for hepatitis C is slightly better, with 36 per cent diagnosed, but treatment rates remain low, with only 20 per cent receiving the curative treatment available.
Despite the daunting statistics, the report offers a glimmer of hope, citing potential returns on investment in preventive measures and treatment initiatives.
According to the report, results obtained from several country investment case studies suggest that strategic action has the potential to achieve a significant reduction in infection rates by 90 per cent, mortality by 65 per cent by 2030, and a 15 per cent decrease in the costs associated with achieving global targets by the same year.
Progress and challenges ahead
While Nigeria grapples with the formidable challenge posed by hepatitis, recent initiatives signal progress in the fight against these infections. The government’s efforts to review treatment guidelines, introduce cost-effective medications, and negotiate price reductions with pharmaceutical companies have yielded promising results.
Additionally, Nigeria’s national immunization program, which includes the hepatitis B birth dose vaccine, represents a critical step in preventing future infections among the population. Furthermore, the approval of self-testing kits for hepatitis C in specific demographics marks a significant milestone, potentially expanding access to essential diagnostic services across the country.
However, significant barriers persist, including the historically high cost of treatment and the need for sustained efforts to enhance awareness, screening, and treatment access nationwide.
See full report here